230 related articles for article (PubMed ID: 30592984)
21. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.
Conrad KP
Hum Reprod Update; 2016 Sep; 22(5):647-64. PubMed ID: 27385360
[TBL] [Abstract][Full Text] [Related]
22. The relaxin receptor RXFP1 signals through a mechanism of autoinhibition.
Erlandson SC; Rawson S; Osei-Owusu J; Brock KP; Liu X; Paulo JA; Mintseris J; Gygi SP; Marks DS; Cong X; Kruse AC
Nat Chem Biol; 2023 Aug; 19(8):1013-1021. PubMed ID: 37081311
[TBL] [Abstract][Full Text] [Related]
23. The relaxin receptor (RXFP1) utilizes hydrophobic moieties on a signaling surface of its N-terminal low density lipoprotein class A module to mediate receptor activation.
Kong RC; Petrie EJ; Mohanty B; Ling J; Lee JC; Gooley PR; Bathgate RA
J Biol Chem; 2013 Sep; 288(39):28138-51. PubMed ID: 23926099
[TBL] [Abstract][Full Text] [Related]
24. Relaxin family peptide receptors Rxfp1 and Rxfp2: mapping of the mRNA and protein distribution in the reproductive tract of the male rat.
Filonzi M; Cardoso LC; Pimenta MT; Queiróz DB; Avellar MC; Porto CS; Lazari MF
Reprod Biol Endocrinol; 2007 Jul; 5():29. PubMed ID: 17623071
[TBL] [Abstract][Full Text] [Related]
25. Using the novel HiBiT tag to label cell surface relaxin receptors for BRET proximity analysis.
Hoare BL; Kocan M; Bruell S; Scott DJ; Bathgate RAD
Pharmacol Res Perspect; 2019 Aug; 7(4):e00513. PubMed ID: 31384473
[TBL] [Abstract][Full Text] [Related]
26. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.
Hu X; Myhr C; Huang Z; Xiao J; Barnaeva E; Ho BA; Agoulnik IU; Ferrer M; Marugan JJ; Southall N; Agoulnik AI
Biochemistry; 2016 Mar; 55(12):1772-83. PubMed ID: 26866459
[TBL] [Abstract][Full Text] [Related]
27. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.
Halls ML; Bathgate RA; Summers RJ
Mol Pharmacol; 2006 Jul; 70(1):214-26. PubMed ID: 16569707
[TBL] [Abstract][Full Text] [Related]
28. Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.
Halls ML
Br J Pharmacol; 2012 Mar; 165(6):1644-1658. PubMed ID: 21557732
[TBL] [Abstract][Full Text] [Related]
29. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway.
Dschietzig T; Bartsch C; Baumann G; Stangl K
Regul Pept; 2009 Apr; 154(1-3):77-84. PubMed ID: 19101597
[TBL] [Abstract][Full Text] [Related]
30. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease.
Samuel CS; Lekgabe ED; Mookerjee I
Adv Exp Med Biol; 2007; 612():88-103. PubMed ID: 18161483
[TBL] [Abstract][Full Text] [Related]
31. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
32. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides.
Bathgate RA; Ivell R; Sanborn BM; Sherwood OD; Summers RJ
Pharmacol Rev; 2006 Mar; 58(1):7-31. PubMed ID: 16507880
[TBL] [Abstract][Full Text] [Related]
33. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
[TBL] [Abstract][Full Text] [Related]
34. Triazine herbicides inhibit relaxin signaling and disrupt nitric oxide homeostasis.
Park SE; Lim SR; Choi HK; Bae J
Toxicol Appl Pharmacol; 2016 Sep; 307():10-18. PubMed ID: 27431321
[TBL] [Abstract][Full Text] [Related]
35. Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes.
Halls ML; Bathgate RA; Summers RJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):281-90. PubMed ID: 17065365
[TBL] [Abstract][Full Text] [Related]
36. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
37. Relaxin abrogates genomic remodeling of the aged heart.
Romero G; Salama G
Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
[TBL] [Abstract][Full Text] [Related]
38. Application of the novel bioluminescent ligand-receptor binding assay to relaxin-RXFP1 system for interaction studies.
Wu QP; Zhang L; Shao XX; Wang JH; Gao Y; Xu ZG; Liu YL; Guo ZY
Amino Acids; 2016 Apr; 48(4):1099-1107. PubMed ID: 26767372
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Sasser JM
Am J Physiol Regul Integr Comp Physiol; 2013 Sep; 305(6):R559-65. PubMed ID: 23883673
[TBL] [Abstract][Full Text] [Related]
40. Chimeric relaxin peptides highlight the role of the A-chain in the function of H2 relaxin.
Hossain MA; Wade JD; Bathgate RA
Peptides; 2012 May; 35(1):102-6. PubMed ID: 22414484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
